See highlights from New General Market Summit keynote presentations delivered by Sundial Brands CEO Rich Dennis, Method and Olly Nutrition co-founder Eric Ryan and Seventh Generation CEO John Replogle.
There is no question that one of the top nonprescription categories contributing to both sales and foot traffic right now is allergy. Sales of nasal sprays — the category that captures all of the latest nasal corticosteroid Rx-to-OTC switches — are up 10.2%.
The reformulation will include Alka-Seltzer Original, Lemon Lime and Extra-Strength effervescent products and the in-store transition will take place following completion of the product reformulation process.
Of the three classes of medicine identified in the Canadian switch report, one is already available OTC in the U.S. and a second is expected to be under consideration for non-prescription status this year.
Sales of all OTC medicines and natural supplements broke records in 2016, reaching $45.8 billion for the 52 weeks ended Dec. 25, 2016, according to IRI. That’s an additional $1.8 billion in sales volume compared with a year ago.
DSN senior editor Michael Johnsen examines the hottest trends in OTC — including breakthrough brands and such growth categories as therables, sleep, allergy, cough-cold and more — in this multi-page report.
Boehringer Ingelheim is looking to spark some excitement across the antacids aisle with the launch of its Duo Fusion combination antacid, which couples a fast-acting heartburn remedy with an H2 blocker to provide both immediate and longer-lasting relief from heartburn.
"Real-world research is a vital component to clinical trials and helps with defining management options for patients," stated Michael Epstein, chief medical advisor for IM HealthScience, which supplies IBgard.